Calendrier des promotions Aadi Bioscience, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Цена ао |
2.2 |
| Выручка |
0.000749 |
| EBITDA |
-0.0225 |
| Число акций ао |
0.02692 млрд |
| P/S |
34.68 |
| P/BV |
0.711 |
| EV/EBITDA |
0.55 |
| ISIN |
US00032Q1040 |
| Сайт |
https://aadibio.com
|
| Валюта |
usd |
| IPO date |
2017-08-08 |
| Sector |
Health Care |
| Industry |
Biotechnology |
| Валюта отчета |
usd |
| Changement de prix par jour: |
0% (2.13) |
| Changement de prix par semaine: |
+7.04% (1.99) |
| Changement de prix par mois: |
+18.33% (1.8) |
| Changement de prix sur 3 mois: |
+39.22% (1.53) |
| Changement de prix sur six mois: |
+15.76% (1.84) |
| Changement de prix par an: |
-46.62% (3.99) |
| Evolution du prix sur 3 ans: |
-92.29% (27.63) |
| Evolution du prix sur 5 ans: |
+204.29% (0.7) |
| Evolution des prix depuis le début de l'année: |
-55.16% (4.75) |
|
|
Sous-estimation
| Nom |
Signification |
Grade |
| P/S |
2.18 |
7 |
| P/BV |
0.5041 |
10 |
| P/E |
0 |
0 |
| EV/EBITDA |
0.0395 |
10 |
| Total: |
|
5.88 |
|
Efficacité
| Nom |
Signification |
Grade |
| ROA, % |
-49.66 |
0 |
| ROE, % |
-62.52 |
0 |
| Total: |
|
0 |
|
|
|
Dividendes
| Nom |
Signification |
Grade |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0 |
|
Devoir
| Nom |
Signification |
Grade |
| Debt/EBITDA |
-0.0979 |
10 |
| Total: |
|
9.8 |
|
Impulsion de croissance
| Nom |
Signification |
Grade |
| Rentabilité Revenue, % |
3151.54 |
10 |
| Rentabilité Ebitda, % |
209.33 |
10 |
| Rentabilité EPS, % |
118.14 |
10 |
| Total: |
|
10 |
|
| ETF |
Partager, % |
Rentabilité pour l'année, % |
Dividendes, % |
| iShares Micro-Cap ETF |
0.00821 |
36.318555985322 |
1.54048 |
|
|
|
|
| Superviseur |
Titre d'emploi |
Paiement |
Année de naissance |
| Dr. Neil P. Desai Ph.D. |
Founder & Executive Chairman |
710.35k |
1965 (59 années) |
| Dr. Loretta M. Itri F.A.C.P., M.D. |
Chief Medical Officer |
617.45k |
1950 (74 année) |
| Mr. David J. Lennon Ph.D. |
President, CEO & Director |
277.75k |
1971 (53 année) |
| Mr. Scott M. Giacobello CPA |
CFO, Treasurer, Investor Relations & Corporate Communications |
643.23k |
1970 (54 année) |
| Mr. Stephen M. Rodin J.D. |
Senior VP of Legal & General Counsel |
N/A |
1976 (48 années) |
| Mr. Raymond G. Steitz |
Senior VP of Human Resources & Chief Human Resources Officer |
N/A |
1959 (65 années) |
| Mr. Bryan Ball |
Chief Technical Operations Officer |
N/A |
1970 (54 année) |
